SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms is trending as investors discuss its recent financing deal involving capped calls, which some believe will fuel expansion while others are skeptical about its use. Community members are debating the potential for dilution and its impact on the stock's future growth, with some drawing comparisons to other Bitcoin miners that have undertaken similar strategies. Bullish sentiment remains strong overall, fueled by the company's shift towards high-performance computing (HPC) and artificial intelligence (AI) infrastructure.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to a lawsuit from Singapore's GIC alleging inflated revenue figures, sparking debate about its impact. The community is divided, with some viewing it as a buying opportunity amidst recycled headlines and others expressing concern. Discussions also include delivery numbers, battery swap technology, and the broader context of Chinese EV competition.

Veritone, Inc. engages in the provision of artificial intelligence (AI) computing solutions to media and entertainment, government, and legal and compliance industries. It operates through the following segments: Advertising, aiWARE SaaS Solutions, and aiWARE Content Licensing and Media Services. The Advertising segment places advertisements for clients, primarily with radio broadcasters, podcasters and digital media producers. The aiWARE SaaS Solutions segment offers solutions through a combination of its direct sales force and indirect channel partners, such as value-added resellers (VARs), distributors, system integrators, managed services providers, and referral partners. The aiWARE Content Licensing and Media Services segment sells and markets activities relating to its digital content licensing services business through its direct sales force. The company was founded by Chad Edward Steelberg and Ryan S. Steelberg on June 13, 2014 and is headquartered in Denver, CO.

Veritone Inc

Veritone (VERI) is trending due to a registered direct offering of $75 million, leading to community discussion about dilution and management's timing. While some investors express concerns about the offering's impact on share value, others view it as a necessary step for growth and debt repayment, emphasizing the company's long-term potential in the AI sector. Community members are actively debating whether this dip presents a buying opportunity or signals further downside.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is trending due to positive topline results from Phase 3 trials of ulixacaltamide HCl for essential tremor, sparking significant pre-market gains and heavy trading volume. The community is focused on the high institutional ownership potentially leading to a short squeeze, with some speculating on price targets. This movement occurs within the context of the essential tremor treatment space, where there is a large unmet need for effective therapies.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

MVST is trending as investors discuss its valuation relative to peers and potential catalysts like earnings and expansion plans. Community members are pointing to potential short squeezes and institutional buying, while also debating the company's ties to China. Overall, the discussion revolves around whether the stock is undervalued and poised for further gains.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending after reporting strong Q3 earnings, driven by surging AI chip demand, and raising its 2025 revenue growth outlook. Community members are discussing the company's impressive profit increase and potential for further gains, while also noting geopolitical risks. Some analysts are raising price targets, citing TSMC's key role in the AI boom and strong guidance.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is trending as the community discusses the potential impact of new partnerships and upcoming earnings. Bullish sentiment is fueled by institutional buying, progress in autonomous trucking technology, and analysts setting high price targets. Discussions also revolve around the company's path to commercialization and its competitive positioning within the autonomous vehicle sector.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as analysts update their ratings, citing a clear path to growth and potential investor sentiment improvement, especially with the company's AI integrations. Community discussions revolve around potential revival of the AI software/enterprise trade and possible short-term trading opportunities. The stock also garnered attention following Salesforce and Google's deepened partnership with Gemini integration, further emphasizing the company's focus on AI.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

ABAT is trending due to the termination of a DOE grant for its lithium hydroxide project, leading to a significant price drop and high trading volume. While the company is appealing the decision and states the project will continue unchanged, the community is debating the impact of the lost funding and potential need for alternative financing. Some investors view the dip as a buying opportunity, citing the company's long-term potential and strategic importance in the domestic battery technology sector.

Virgin Galactic Holdings, Inc. is an aerospace and space travel company, which engages in the provision of consumer space experience using reusable spaceflight systems. The firm is also involved in designing, developing, and manufacturing, ground and flight testing, spaceflight operation, and post-flight maintenance of spaceflight systems. The company was founded on May 5, 2017 and is headquartered in Tustin, CA.

Virgin Galactic Holdings Inc - Ordinary Shares - Class A

Virgin Galactic Holdings Inc

SPCE is experiencing high trading volume, with community members discussing technical indicators like MACD and EMA. Some are pointing to a potential breakout above key resistance levels, while others remain skeptical due to past performance and dilution concerns. Overall, the increased activity may be linked to anticipation surrounding upcoming flights and the company's future prospects in space tourism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Equity

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.


Nasdaq-listed shares of UK-based TC BioPharm (Holdings) PLC (TCBP) tumbled 64% by Friday afternoon after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tcbp-announces-transition-from-nasdaq-to-otc-markets-302408102.html">said</a> its securities would be delisted from the exchange.The delisting follows the company’s failure to maintain a minimum bid price of $1 per share. The company said that its management is working on an appeal with Nasdaq and expressed optimism that its American Depositary Shares will be eligible to trade on the OTC markets starting Monday.Earlier this week, the company announced a reduction in its workforce and other measures aimed at reducing core operational burn by 55% compared to last year. The layoff impacted approximately 20 employees, or <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tcbiopharm.com/news/press-releases/detail/122/tcbp-announces-outsourcing-initiatives-reducing-burn-rate">half of the company’s total headcount</a>.On Stocktwits, investors expressed frustration over the news.&nbsp;<stembedurl>https://stocktwits.com/Blackdog111/message/608838652</stembedurl>One user opined that there is little chance for recovery for the company’s stock.<stembedurl>https://stocktwits.com/Oxinternet/message/608832026</stembedurl>In early March, TC BioPharm announced that it had executed a non-binding letter of intent to acquire 100% of a commercial-stage ophthalmic pharmaceutical company in an all-stock transaction.CEO Bryan Kobel said the firm expects to execute the binding letter of intent in a few weeks and close the acquisition around the third quarter of this year.At the beginning of 2025, Kobel <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tcbp-issues-25-stock-dividend-302340235.html">said</a> he anticipated 2025 to be a “period of growth and development” for the company. He expressed “strong confidence” in the company’s financial future after issuing a special dividend of 0.25 &nbsp;American Depositary Shares (ADSs) for every ADS held by shareholders.&nbsp;The stock has dropped by over 94% this year, wiping nearly all its value over the past twelve months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rio-tinto-eyes-bigger-us-footprint-amid-copper-price-surge-fueled-by-trump-tariffs/ch7oTeGRb53">Rio Tinto Reportedly Eyes Bigger US Footprint Amid Copper Price Surge Fueled By Trump Tariffs – Stock Drops, Retail Sentiment Weakens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

TC BioPharm Stock Crashes On Nasdaq Delisting: Retail Expresses Frustration

The company said that its management is working on an appeal with Nasdaq and expressed optimism that its American Depositary Shares will be eligible to trade on the OTC markets starting Monday.

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life...

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial PR Newswire EDINBURGH, Scotland, Feb. 13...

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical...

TCBP to Implement ADS Ratio Change

TCBP to Implement ADS Ratio Change TCBP to Implement ADS Ratio Change PR Newswire EDINBURGH, Scotland, Feb. 5, 2025 EDINBURGH, Scotland, Feb. 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ('TC...

TCBP Announces H5N1 Proof of Concept Studies Intention

TCBP Announces H5N1 Proof of Concept Studies Intention TCBP Announces H5N1 Proof of Concept Studies Intention PR Newswire EDINBURGH, Scotland, Jan. 15, 2025 EDINBURGH, Scotland, Jan. 15, 2025...

TCBP to Present at Sequire Investor Summit 2025

TCBP to Present at Sequire Investor Summit 2025 TCBP to Present at Sequire Investor Summit 2025 PR Newswire EDINBURGH, Scotland, Jan. 13, 2025 EDINBURGH, Scotland, Jan. 13, 2025 /PRNewswire/ -- TC...

TCBP Trading Continues Unabated on Nasdaq Stock Exchange

TCBP Trading Continues Unabated on Nasdaq Stock Exchange TCBP Trading Continues Unabated on Nasdaq Stock Exchange PR Newswire EDINBURGH, Scotland, Jan. 6, 2025 EDINBURGH, Scotland, Jan. 6, 2025...

TCBP Provides Update on Acquisition Strategy and Current Targets

TCBP Provides Update on Acquisition Strategy and Current Targets TCBP Provides Update on Acquisition Strategy and Current Targets PR Newswire EDINBURGH, Scotland, Dec. 31, 2024 EDINBURGH, Scotland...

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

TC BioPharm (Holdings) plc - ADR

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$0.235
Prev Close	$0.2001
Open	$0.235
Dividend Yield	0.00%
50-Day Moving Average	$0.249
Beta	0.69
Avg. Volume	9,719.29
PE Ratio	0.00

52-Week High	$83.93
52-Week Low	$0.08
Market Capitalization	$149,860.00
EPS (Annual)	-$164.58
Price to Book	0.12
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TCBP
TC BioPharm Holdings Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest TCBP News

TCBPTC BioPharm Holdings Ltd